Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma.
Cancer
Human
Immunohistochemistry
PDE5 inhibitor
Phosphodiesterase
prostate
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
15
05
2019
revised:
17
07
2019
accepted:
18
07
2019
pubmed:
23
8
2019
medline:
20
1
2021
entrez:
22
8
2019
Statut:
ppublish
Résumé
Type 5 phosphodiesterase (PDE5) expression in the normal and pathological prostate is controversial. This study aimed at identifying the cell type/s, if any, expressing PDE5 in human healthy or pathological prostate sections in order to further validate the rationale of PDE5 inhibitor (PDE5i) treatment of benign prostatic hyperplasia (BPH) and their safety in the treatment of erectile dysfunction following prostate cancer (PCa) surgery. By immunohistochemical analysis, we studied PDE5 expression in tissue microarrays containing sections obtained from healthy, BPH, and PCa samples. Our results showed that PDE5 is barely expressed in the epithelial or stromal compartment of normal human prostates, but it is highly expressed in the stromal compartment of BPH sections. We also found that a low but significant number of PCa samples (22%) expressed PDE5 in the epithelial cancer cells but not in stromal cells and that such expression was not correlated with the tumor aggressiveness, according to their Gleason score. PDE5 overexpression in the stromal compartment of BPH samples supports the rationale of PDE5 as a target in lower urinary tract symptoms of BPH. PDE5 expression in a significant percentage of PCa samples but the lack of correlation with the Gleason score suggests that this enzyme is not correlated with tumor aggressiveness; however, a role of PDE5 in the minimal residual disease of PCa cannot be excluded.
Sections du résumé
BACKGROUND
Type 5 phosphodiesterase (PDE5) expression in the normal and pathological prostate is controversial.
OBJECTIVES
This study aimed at identifying the cell type/s, if any, expressing PDE5 in human healthy or pathological prostate sections in order to further validate the rationale of PDE5 inhibitor (PDE5i) treatment of benign prostatic hyperplasia (BPH) and their safety in the treatment of erectile dysfunction following prostate cancer (PCa) surgery.
MATERIALS AND METHODS
By immunohistochemical analysis, we studied PDE5 expression in tissue microarrays containing sections obtained from healthy, BPH, and PCa samples.
RESULTS
Our results showed that PDE5 is barely expressed in the epithelial or stromal compartment of normal human prostates, but it is highly expressed in the stromal compartment of BPH sections. We also found that a low but significant number of PCa samples (22%) expressed PDE5 in the epithelial cancer cells but not in stromal cells and that such expression was not correlated with the tumor aggressiveness, according to their Gleason score.
DISCUSSION AND CONCLUSION
PDE5 overexpression in the stromal compartment of BPH samples supports the rationale of PDE5 as a target in lower urinary tract symptoms of BPH. PDE5 expression in a significant percentage of PCa samples but the lack of correlation with the Gleason score suggests that this enzyme is not correlated with tumor aggressiveness; however, a role of PDE5 in the minimal residual disease of PCa cannot be excluded.
Substances chimiques
Cyclic Nucleotide Phosphodiesterases, Type 5
EC 3.1.4.35
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
427-433Subventions
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : 215XCR88M
Pays : International
Organisme : University of Rome Torvergata 'Consolidate the Foundation'
Pays : International
Informations de copyright
© 2019 American Society of Andrology and European Academy of Andrology.
Références
Barone I, Giordano C, Bonofiglio D, Catalano S & Andò S. (2015) Phosphodiesterase type 5 as a candidate therapeutic target in cancers. Curr Pathobiol Rep 3, 193-201.
Barone I, Giordano C, Bonofiglio D, Andò S & Catalano S. (2017) Phosphodiesterase type 5 and cancers: progress and challenges. Oncotarget 8, 99179-99202.
Beavo JA. (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75, 725-748.
Blander DS, Sanchez-Ortiz RF, Wein AJ & Broderick GA. (2000) Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int J Impot Res 12, 165-168.
Briganti A & Montorsi F. (2006) Penile rehabilitation after radical prostatectomy. Nat Clin Pract Urol 3, 400-401.
Briganti A, Salonia A, Zanni G, Fabbri F, Saccà A, Bertini R, Suardi N, Fantini GV, Rigatti P & Montorsi F. (2004) Erectile dysfunction and radical prostatectomy: an update. EAU Update Ser 2, 84-92.
Brock G, Nehra A, Lipshultz L, Karlin G, Gleave M, Seger M & Padma-Nathan H. (2003) Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 170, 1278-1283.
Cesarini V, Martini M, Vitiani LR, Gravina GL, Di Agostino S, Graziani G, D'Alessandris QG, Pallini R, Larocca LM, Rossi P, Jannini EA & Dolci S. (2017) Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. Oncotarget 8, 13223-13239.
Dolci S, Belmonte A, Santone R, Giorgi M, Pellegrini M, Carosa E, Piccione E, Lenzi A & Jannini EA. (2006) Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. Biochem Biophys Res Comm 341, 837-846.
Donatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD & Viktrup L. (2011) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int 107, 1110-1116.
Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM, Schröder FH & de Koning HJ. (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95, 868-878.
Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG & Secrest RJ. (2012) Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 9, 271-281.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA & Grading Committee. (2015) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 40, 1.
Feng MI, Huang S, Kaptein J, Kaswick J & Aboseif S. (2000) Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction. J Urol 164, 1935-1938.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D & Bray F. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49, 1374-1403.
Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P & Maggi M. (2010) Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 7, 59-69.
Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. (2018) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016. JAMA Oncol 4, 1553-1568.
Gallina A, Bianchi M, Gandaglia G, Cucchiara V, Suardi N, Montorsi F & Briganti A. (2015) A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy. Eur Urol 68, 750-753.
Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM & Kaplan RS. (1999) Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91, 1017-1024.
Hong EK, Lepor H & McCullough AR. (1999) Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). nature.com.
Horst C, Martinez-Portillo FJ & Jünemann KP. (2005) Pathophysiologie und rehabilitation der erektilen dysfunktion nach nerverhaltender radikaler prostatektomie. Der Urologe, Ausgabe A 44, 667-673.
Jannini EA, Isidori AM, Gravina GL, Aversa A, Balercia G, Bocchio M, Boscaro M, Carani C, Corona G, Fabbi A, Foresta C, Forti G, Francavilla S, Granata AR, Maggi M, Mansani R, Palego F, Spera G, Vetri M, Lenzi A. (2009) The ENDOTRIAL Study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 6, 2547-2560.
Li W-Q, Qureshi AA, Robinson KC & Han J. (2014) Sildenafil use and increased risk of incident melanoma in US men. JAMA Intern Med 174, 964.
Limoncin E, Gravina GL, Corona G, Maggi M, Ciocca G, Lenzi A & Jannini EA. (2017) Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis. Andrology 5, 863-872.
Lin C-S, Lau A, Tu R & Lue TF. (2000) Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Comm 268, 628-635.
Lowentritt BH, Scardino PT, Miles BJ, Orejuela FJ, Schatte EC, Slawin KM, Elliott SP & Kim ED. (1999) Sildenafil citrate after radical retropubic prostatectomy. J Urol 162, 1614-1617.
Mendenhall WM, Nichols RC, Henderson R & Mendenhall NP. (2010) Is radical prostatectomy the “gold standard” for localized prostate cancer? Am J Clin Oncol 33, 511-515.
Mónica FZ & De Nucci G. (2019) Tadalafil for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother 1-9.
Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M & Stief C. (2008) Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 54, 924-931.
Montorsi F, Brock G, Stolzenburg J-U, Mulhall J, Moncada I, Patel HRH, Chevallier D, Krajka K, Henneges C, Dickson R & Büttner H. (2014) Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol 65, 587-596.
Moskovic DJ, Miles BJ, Lipshultz LI & Khera M. (2011) Emerging concepts in erectile preservation following radical prostatectomy: a guide for clinicians. Int J Impot Res 23, 181-192.
Murthy KS. (2001) Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J 360, 199-208.
Oelke M, Giuliano F, Mirone V, Xu L, Cox D & Viktrup L. (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61, 917-925.
Pisansky TM, Pugh SL, Greenberg RE, Pervez N, Reed DR, Rosenthal SA, Mowat RB, Raben A, Buyyounouski MK, Kachnic LA, et al. (2014) Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer. JAMA 311, 1300.
Potosky AL, Kessler L, Gridley G, Brown CC & Horm JW. (1990) Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 82, 1624-1628.
Potosky AL, Miller BA, Albertsen PC & Kramer BS. (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273, 548-552.
Raina R, Lakin M, Agarwal A, Sharma R & Urology KG. (2003) Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up1. goldjournal.net.
Roston AB, Helenowski IB, Catalona W, Leikin R, Gurley M, Trapp L, Jovanovic B & Kuzel TM. (2017) Impact of use of phosphodiesterase type 5 inhibitors (PDE5-I) after radical prostatectomy (RP) on biochemical recurrence-free (BCRF) and overall survival (OS): a retrospective study from the Northwestern University SPORE in prostate cancer. J Clin Oncol 35, 27-27.
Saleh A, Abboudi H, Ghazal-Aswad M, Mayer EK & Vale JA. (2015) Management of erectile dysfunction post-radical prostatectomy. Res Rep Urol 7, 19-33.
Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP & Stief C. (2012) Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol 62, 273-286.
Shkolyar E, Li S, Tang J & Eisenberg ML. (2018) Risk of melanoma with phosphodiesterase type 5 inhibitor use among patients with erectile dysfunction, pulmonary hypertension, and lower urinary tract symptoms. J Sex Med 15, 982-989.
Siegel RL, Miller KD & Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68, 7-30.
Soderling SH & Beavo JA. (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12, 174-179.
Thorpe A & Neal D. (2003) Benign prostatic hyperplasia. Lancet 361, 1359-1367.
Ückert S, Oelke M, Stief CG, Andersson K-E, Jonas U & Hedlund P. (2006) Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49, 740-745.
Wang J, Shen Y, Wang J, Xue Y, Liao L, Thapa S & Ji K. (2017) Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review. Oncotarget 8, 46461-46467.
Zenzmaier C, Sampson N, Pernkopf D, Plas E, Untergasser G & Berger P. (2010) Attenuated proliferation and Trans -differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. Endocrinology 151, 3975-3984.
Zenzmaier C, Kern J, Sampson N, Heitz M, Plas E, Untergasser G & Berger P. (2012) Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast Trans -differentiation. Endocrinology 153, 5546-5555.
Zhang W, Zang N, Jiang Y, Chen P, Wang X & Zhang X. (2016) Upregulation of phosphodiesterase type 5 in the hyperplastic prostate. Sci Rep 5, 17888.
Zippe CD, Jhaveri FM, Klein EA, Kedia S, Pasqualotto FF, Kedia A, Agarwal A, Montague DK & Lakin MM. (2000) Role of Viagra after radical prostatectomy. Urology 55, 241-245.